Cargando…
The Treatment of Peritoneal Carcinomatosis in Advanced Gastric Cancer: State of the Art
Gastric cancer (GC) is the fourth most common cancer and the second leading cause of cancer death in the world; 53–60% of patients show disease progression and die of peritoneal carcinomatosis (PC). PC of gastric origin has an extremely inauspicious prognosis with a median survival estimate at 1–3 m...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947693/ https://www.ncbi.nlm.nih.gov/pubmed/24693422 http://dx.doi.org/10.1155/2014/912418 |
_version_ | 1782306707062390784 |
---|---|
author | Montori, Giulia Coccolini, Federico Ceresoli, Marco Catena, Fausto Colaianni, Nicola Poletti, Eugenio Ansaloni, Luca |
author_facet | Montori, Giulia Coccolini, Federico Ceresoli, Marco Catena, Fausto Colaianni, Nicola Poletti, Eugenio Ansaloni, Luca |
author_sort | Montori, Giulia |
collection | PubMed |
description | Gastric cancer (GC) is the fourth most common cancer and the second leading cause of cancer death in the world; 53–60% of patients show disease progression and die of peritoneal carcinomatosis (PC). PC of gastric origin has an extremely inauspicious prognosis with a median survival estimate at 1–3 months. Different studies presented contrasting data about survival rates; however, all agreed with the necessity of a complete cytoreduction to improve survival. Hyperthermic intraperitoneal chemotherapy (HIPEC) has an adjuvant role in preventing peritoneal recurrences. A multidisciplinary approach should be empowered: the association of neoadjuvant intraperitoneal and systemic chemotherapy (NIPS), cytoreductive surgery (CRS), HIPEC, and early postoperative intraperitoneal chemotherapy (EPIC) could increase the rate of completeness of cytoreduction (CC) and consequently survival rates, especially in patients with Peritoneal Cancer Index (PCI) ≤6. Neoadjuvant chemotherapy may improve survival also in PC from GC and adjuvant chemotherapy could prevent recurrence. In the last decade an interesting new drug, called Catumaxomab, has been developed in Germany. Two studies showed that this drug seems to improve progression-free survival in patients with GC; however, final results for both studies have still to be published. |
format | Online Article Text |
id | pubmed-3947693 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-39476932014-04-01 The Treatment of Peritoneal Carcinomatosis in Advanced Gastric Cancer: State of the Art Montori, Giulia Coccolini, Federico Ceresoli, Marco Catena, Fausto Colaianni, Nicola Poletti, Eugenio Ansaloni, Luca Int J Surg Oncol Review Article Gastric cancer (GC) is the fourth most common cancer and the second leading cause of cancer death in the world; 53–60% of patients show disease progression and die of peritoneal carcinomatosis (PC). PC of gastric origin has an extremely inauspicious prognosis with a median survival estimate at 1–3 months. Different studies presented contrasting data about survival rates; however, all agreed with the necessity of a complete cytoreduction to improve survival. Hyperthermic intraperitoneal chemotherapy (HIPEC) has an adjuvant role in preventing peritoneal recurrences. A multidisciplinary approach should be empowered: the association of neoadjuvant intraperitoneal and systemic chemotherapy (NIPS), cytoreductive surgery (CRS), HIPEC, and early postoperative intraperitoneal chemotherapy (EPIC) could increase the rate of completeness of cytoreduction (CC) and consequently survival rates, especially in patients with Peritoneal Cancer Index (PCI) ≤6. Neoadjuvant chemotherapy may improve survival also in PC from GC and adjuvant chemotherapy could prevent recurrence. In the last decade an interesting new drug, called Catumaxomab, has been developed in Germany. Two studies showed that this drug seems to improve progression-free survival in patients with GC; however, final results for both studies have still to be published. Hindawi Publishing Corporation 2014 2014-02-17 /pmc/articles/PMC3947693/ /pubmed/24693422 http://dx.doi.org/10.1155/2014/912418 Text en Copyright © 2014 Giulia Montori et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Montori, Giulia Coccolini, Federico Ceresoli, Marco Catena, Fausto Colaianni, Nicola Poletti, Eugenio Ansaloni, Luca The Treatment of Peritoneal Carcinomatosis in Advanced Gastric Cancer: State of the Art |
title | The Treatment of Peritoneal Carcinomatosis in Advanced Gastric Cancer: State of the Art |
title_full | The Treatment of Peritoneal Carcinomatosis in Advanced Gastric Cancer: State of the Art |
title_fullStr | The Treatment of Peritoneal Carcinomatosis in Advanced Gastric Cancer: State of the Art |
title_full_unstemmed | The Treatment of Peritoneal Carcinomatosis in Advanced Gastric Cancer: State of the Art |
title_short | The Treatment of Peritoneal Carcinomatosis in Advanced Gastric Cancer: State of the Art |
title_sort | treatment of peritoneal carcinomatosis in advanced gastric cancer: state of the art |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947693/ https://www.ncbi.nlm.nih.gov/pubmed/24693422 http://dx.doi.org/10.1155/2014/912418 |
work_keys_str_mv | AT montorigiulia thetreatmentofperitonealcarcinomatosisinadvancedgastriccancerstateoftheart AT coccolinifederico thetreatmentofperitonealcarcinomatosisinadvancedgastriccancerstateoftheart AT ceresolimarco thetreatmentofperitonealcarcinomatosisinadvancedgastriccancerstateoftheart AT catenafausto thetreatmentofperitonealcarcinomatosisinadvancedgastriccancerstateoftheart AT colaianninicola thetreatmentofperitonealcarcinomatosisinadvancedgastriccancerstateoftheart AT polettieugenio thetreatmentofperitonealcarcinomatosisinadvancedgastriccancerstateoftheart AT ansaloniluca thetreatmentofperitonealcarcinomatosisinadvancedgastriccancerstateoftheart AT montorigiulia treatmentofperitonealcarcinomatosisinadvancedgastriccancerstateoftheart AT coccolinifederico treatmentofperitonealcarcinomatosisinadvancedgastriccancerstateoftheart AT ceresolimarco treatmentofperitonealcarcinomatosisinadvancedgastriccancerstateoftheart AT catenafausto treatmentofperitonealcarcinomatosisinadvancedgastriccancerstateoftheart AT colaianninicola treatmentofperitonealcarcinomatosisinadvancedgastriccancerstateoftheart AT polettieugenio treatmentofperitonealcarcinomatosisinadvancedgastriccancerstateoftheart AT ansaloniluca treatmentofperitonealcarcinomatosisinadvancedgastriccancerstateoftheart |